The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
ACADEMIA
4 Scientific Societies Submit Proposal to Health Minister to Ensure Stable Antibiotic Supplies
Four scientific societies have submitted a proposal for the stable supply of antibiotics to the health minister, calling on the government to keep tabs on the production systems for such drugs and to evaluate the risks of sudden supply stoppages.…
To read the full story
Related Article
- 1st Working Group Meeting for Prioritization of “Stable Supply Medicines” Set for Early November
October 26, 2020
- MHLW Panel Roughly OKs Report on Stable API Supply Measures
August 31, 2020
- Japan Sketches Out Stable API Supply Measures, Set to Pick Key Drugs from 551 Candidates by March-End
August 4, 2020
- 418 Key Drug Candidates Listed by 36 Societies, Panel to Outline Stable Supply Measures at Next Meeting
June 29, 2020
- Stable Supply Debate Set to Heat Up in Japan, Scientific Societies to Select Key Drugs by June-End
June 9, 2020
- New Stable Supply Panel Wants to Define “Key Drugs” by This Summer
March 30, 2020
- 3 Key Antibiotics to Receive Price Raises through Unprofitability Re-Pricing
March 18, 2020
- Decision on Whether Antibiotics Are Manufactured in Japan or Overseas Should be Left to Drug Makers: Govt
October 28, 2019
ACADEMIA
- Taking on Solid Tumors - 1: Japan Sees Rush of Bispecific Approvals with Good Progress in Blood Cancers, and More
May 27, 2025
- Japan Consortium to Promote Domestic R&D of Cannabis-Derived Meds
May 14, 2025
- CGP Test Data for Over 100,000 Patients Now on National Database
May 13, 2025
- Diabetes Society Flags DKA Risk for AstraZeneca’s Truqap after Report of Death
April 21, 2025
- iPSC-Derived Cells Effective in Parkinson’s, Approval Could Come in FY2025
April 21, 2025
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…